Methods for Treating Allergic Asthma Through KIT Kinase and Mast Cell Tryptase Inhibition in Bronchial Airway Mast Cells Identified by Single-Cell Transcriptomic Analysis — USPTO Provisional Patent Specification

Read full text Summarise with VIRAT
Authors: Glen Charles Ritschel, Claude
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Provisional patent specification (Ritschel Research, filed 2026) disclosing methods and compositions for treating allergic asthma through inhibition of KIT kinase (CD117) and mast cell tryptase (TPSAB1) in bronchial airway mast cells identified by single-cell RNA sequencing. A computational pipeline was applied to the human bronchial brushing scRNA-seq dataset GSE193816 (48,873 cells, 21 samples; Alladina et al., Science Immunology 2023). ScVI dimensionality reduction and Leiden clustering identified 20 cell populations; a bronchial mast cell signature identified clusters 15 and 17 with mean scores of 1.164 and 0.370. Wilcoxon differential expression yielded 899 upregulated genes including KIT, TPSAB1 (log2FC 12.3), TPSB2 (11.6), CPA3 (12.8), and MS4A2 (10.6). ChEMBL screening identified 4,452 NOVEL_ALL candidates across 8 targets. Lead KIT inhibitors: CHEMBL4448433 (pChEMBL 10.70), sunitinib (9.68), avapritinib (9.62, FDA-approved for systemic mastocytosis), axitinib (9.31), dasatinib (9.24). All confirmed NOVEL_ALL for the allergic asthma / bronchial mast cell indication. Pipeline: github.com/glenritschel/asthma-scrna.

Fields of Study & Subjects

Mast cells and histamine Asthma and respiratory diseases Allergic Rhinitis and Sensitization

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
23 March 2026
Language
EN